White paper - Value and challenges of the European medical industry in Australia
Abstract
Insights from a pharma roundtable by German, Swiss & French Chambers with top leaders shaping Australia’s life sciences sector.
Summary
In August 2024, the French, German and Swiss Chambers of Commerce in Australia brought together their pharmaceutical and life sciences members for a landmark roundtable at Sanofi’s Sydney headquarters. This white paper distils the outcomes of that event, offering a unique European perspective on the opportunities and structural barriers facing pharmaceutical companies operating in Australia.
Despite its strengths in early-stage trials and a skilled clinical workforce, Australia’s complex regulatory environment and slow reimbursement system remain major hurdles for international drug developers. The insights gathered in this document offer a roadmap to creating a more attractive, collaborative and efficient market.
Inside this white paper:
– Comparative analysis of Australia’s clinical trial advantages and regional competition
– The impact of PBS delays on market access and global launch decisions
– Supply sustainability challenges and pricing policy uncertainties
– Policy recommendations for faster reimbursement pathways and stronger commercialisation
– Why Australia must reframe health expenditure as long-term investment, not cost